Adalimumab Total Anti-Drug Antibody ELISA
$1,053.00
Catalog
30-ADTHU-E01
The Adalimumab Total Anti-Drug Antibody ELISA is intended for the semi-quantitative determination of total anti-drug antibodies against Humira® in human serum and EDTA plasma. Health Canada Licensed , Research Use Only. Not for Use in Diagnostic Procedures.
Species
Human
Regulatory Status
Health Canada Licensed, Research Use Only. Not for Use in Diagnostic Procedures.
Product Distribution
Available in North America Only
Sizes
96 Wells
Sample Types
EDTA Plasma, Serum
Inc Time Hour
1
Inc Time Minute
50
Inc Time Overnight
No
Inc Time See Protocol
No
Sample Size
100
Detection
Colorimetric
This ELISA is designed for the semi-quantitative determination of antibodies against TNF-alpha blocker adalimumab (Humira® ). During sample preparation, the anti-drug antibodies (ADA) are separated from the therapeutic antibody to acquire free ADA. By adding the peroxidase conjugate (peroxidase labelled therapeutic antibody) and the tracer (biotinylated therapeutic antibody), the unmarked therapeutic antibodies are replaced and the marked antibodies can form a complex with the ADA. This complex binds via biotin to the streptavidin coated microtiter plate. It is detected via the peroxidase conjugate with the peroxidase converting the substrate TMB to a blue product. The enzymatic reaction is stopped by adding an acidic solution. The samples convert from blue to yellow. The color change should be measured in a photometer at 450 nm. The interpretation is made using the cut-off control.